Open AccessExposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials
Author(s) -
Ruth N. Moro,
Nigel Scott,
Andrew Ver,
Naomi K. Tepper,
Stefan Goldberg,
Kevin Schwartzman,
Chi Chiu Leung,
Neil W. Schluger,
Robert Belknap,
Richard E. Chaisson,
Michiko Narita,
Elizabeth S. Machado,
Marta López,
Jorge Sánchez,
Margarita E. Villarino,
Timothy R. Sterling
Publication year - 2018
Publication title -
annals of the american thoracic society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 114
eISSN - 2329-6933
pISSN - 2325-6621
DOI - 10.1513/annalsats.201704-326oc
Subject(s) - medicine , isoniazid , pregnancy , rifapentine , confidence interval , fetus , tuberculosis , obstetrics , latent tuberculosis , pediatrics , mycobacterium tuberculosis , genetics , pathology , biology
Data are limited regarding the safety of 12-dose once-weekly isoniazid (H, 900 mg) plus rifapentine (P, 900 mg) (3HP) for latent infection treatment during pregnancy.